Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with EGFR-TKI after EGFR-TKI resistance in EGFR-mutant patients
ChiCTR1800017863Phase 4Recruiting
- Sponsor
- Tangshan People's Hospital
- Start
- Aug 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in EGFR-Mutant Non-Small-Cell Lung Cancer, sponsored by Tangshan People's Hospital. Primary endpoint: Progression-free survival. Started Aug 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
EGFR-Mutant Non-Small-Cell Lung Cancer
Beyond the preview
Go deeper on ChiCTR1800017863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017863.